ACAT1 and neoplasm: Importantly, depleting B cells with an anti-CD20 antibody or inhibiting TLS formation with TAK-799 (also known as TAK-779), an inhibitor of CCR5 and CXCL13/CXCR5, abolished Acat1 knockdown–induced TLS formation and tumor control.